BRITISH BIOTECH IND FOR STEM CELL PROTECTOR BB-10010 APPROVED

Executive Summary

BRITISH BIOTECH IND FOR STEM CELL PROTECTOR BB-10010 APPROVED Nov. 30, Chief Financial Officer James Noble told the annual Robertson, Stephens medical conference in New York City Dec. 1. "We'll be putting forward clinical trials at Indiana [University Medical Center] very shortly, I hope in the next couple of weeks," Noble continued. BB-10010 is a "genetically engineered variant" of "a natural stem cell protector in bone marrow," LD78, Noble said. British Biotechnology is pursuing "two different clinical programs" for the compound: stem cell protection and stem cell mobilization.